Published in Cancer Res on May 18, 2010
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res (2011) 3.25
Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Dev Cell (2017) 1.40
Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron (2011) 1.37
Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 1.34
Cell intercalation from top to bottom. Nat Rev Mol Cell Biol (2014) 1.25
Epigenetic disruption of cadherin-11 in human cancer metastasis. J Pathol (2012) 1.14
Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front Biosci (Landmark Ed) (2011) 1.12
Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer (2014) 1.07
The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/β-catenin signaling and silenced in common carcinomas. Oncogene (2011) 1.00
Cadherin-11, a marker of the mesenchymal phenotype, regulates glioblastoma cell migration and survival in vivo. Mol Cancer Res (2012) 0.97
Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes Cancer (2011) 0.97
HOXC8-Dependent Cadherin 11 Expression Facilitates Breast Cancer Cell Migration through Trio and Rac. Genes Cancer (2011) 0.93
Development of a method to isolate circulating tumor cells using mesenchymal-based capture. Methods (2013) 0.92
Homing of cancer cells to the bone. Cancer Microenviron (2011) 0.92
The gap junction protein Cx43 is involved in the bone-targeted metastatic behaviour of human prostate cancer cells. Clin Exp Metastasis (2011) 0.90
Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer. Open Prost Cancer J (2010) 0.90
Aurora B is regulated by acetylation/deacetylation during mitosis in prostate cancer cells. FASEB J (2012) 0.89
The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis. Front Oncol (2014) 0.87
Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Curr Mol Med (2013) 0.87
Inhibition of cell adhesion by a cadherin-11 antibody thwarts bone metastasis. Mol Cancer Res (2013) 0.86
HOXC8 promotes breast tumorigenesis by transcriptionally facilitating cadherin-11 expression. Oncotarget (2014) 0.86
New therapeutic targets for cancer bone metastasis. Trends Pharmacol Sci (2015) 0.86
RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival. Mol Cancer Res (2014) 0.85
Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. Oncotarget (2014) 0.85
Cadherin-11 in renal cell carcinoma bone metastasis. PLoS One (2014) 0.85
N-cadherin dependent collective cell invasion of prostate cancer cells is regulated by the N-terminus of α-catenin. PLoS One (2013) 0.84
Development of a surface plasmon resonance biosensor for real-time detection of osteogenic differentiation in live mesenchymal stem cells. PLoS One (2011) 0.84
Angiomotin is a novel component of cadherin-11/β-catenin/p120 complex and is critical for cadherin-11-mediated cell migration. FASEB J (2014) 0.83
Downstream signaling and genome-wide regulatory effects of PTK7 pseudokinase and its proteolytic fragments in cancer cells. Cell Commun Signal (2014) 0.83
Targeting bone physiology for the treatment of metastatic prostate cancer. Clin Adv Hematol Oncol (2013) 0.80
Cadherin-11 Overexpression Induces Extracellular Matrix Remodeling and Calcification in Mature Aortic Valves. Arterioscler Thromb Vasc Biol (2016) 0.79
Bone Metastasis from Renal Cell Carcinoma. Int J Mol Sci (2016) 0.79
Structure and function of the solid tumor niche. Front Biosci (Schol Ed) (2012) 0.78
Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer. Oncotarget (2015) 0.78
Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies. Clin Exp Metastasis (2013) 0.78
Three-dimensional (3D) culture of bone-derived human 786-O renal cell carcinoma retains relevant clinical characteristics of bone metastases. Cancer Lett (2015) 0.77
Cadherin-11 regulates the metastasis of Ewing sarcoma cells to bone. Clin Exp Metastasis (2015) 0.77
ADAM13 cleavage of cadherin-11 promotes CNC migration independently of the homophilic binding site. Dev Biol (2015) 0.77
Cadherins mediate sequential roles through a hierarchy of mechanisms in the developing mammillary body. Front Neuroanat (2015) 0.77
Beta-actin is required for proper mouse neural crest ontogeny. PLoS One (2014) 0.76
The expression and activity of thioredoxin reductase 1 splice variants v1 and v2 regulate the expression of genes associated with differentiation and adhesion. Biosci Rep (2015) 0.76
Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer. Cytokine (2016) 0.76
Cadherin-11 expression is upregulated in invasive human breast cancer. Oncol Lett (2016) 0.75
Cadherin-11 Is a Cell Surface Marker Up-Regulated in Activated Pancreatic Stellate Cells and Is Involved in Pancreatic Cancer Cell Migration. Am J Pathol (2016) 0.75
Cadherin-11 endocytosis through binding to clathrin promotes cadherin-11-mediated migration in prostate cancer cells. J Cell Sci (2015) 0.75
T-cadherin in prostate cancer: relationship with cancer progression, differentiation and drug resistance. J Pathol Clin Res (2016) 0.75
Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function. Mol Clin Oncol (2015) 0.75
Collagen triple helix repeat containing 1 is a new promigratory marker of arthritic pannus. Arthritis Res Ther (2016) 0.75
Snail1 expression in human colon cancer DLD-1 cells confers invasive properties without N-cadherin expression. Biochem Biophys Rep (2016) 0.75
A guide to choosing fluorescent proteins. Nat Methods (2005) 18.55
Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol (2005) 9.27
Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell (1991) 8.75
E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol (1991) 8.60
A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature (1998) 8.48
Cell binding function of E-cadherin is regulated by the cytoplasmic domain. EMBO J (1988) 7.98
Morphogenetic roles of classic cadherins. Curr Opin Cell Biol (1995) 6.95
Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol (1994) 5.93
In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol (1983) 5.39
Transmembrane control of cadherin-mediated cell adhesion: a 94 kDa protein functionally associated with a specific region of the cytoplasmic domain of E-cadherin. Cell Regul (1989) 4.72
The juxtamembrane region of the cadherin cytoplasmic tail supports lateral clustering, adhesive strengthening, and interaction with p120ctn. J Cell Biol (1998) 4.38
N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol (1999) 4.20
Cadherin switching. J Cell Sci (2008) 3.70
Cadherin-11 in synovial lining formation and pathology in arthritis. Science (2007) 3.25
Cadherin switching in human prostate cancer progression. Cancer Res (2000) 2.80
LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate (2000) 2.79
Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer (1998) 2.36
Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res (1987) 2.03
Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res (1999) 1.97
Molecular cloning and characterization of OB-cadherin, a new member of cadherin family expressed in osteoblasts. J Biol Chem (1994) 1.70
Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res (2008) 1.67
Morphological and biochemical characterization of four clonal osteogenic sarcoma cell lines of rat origin. Cancer Res (1983) 1.38
N-cadherin as a therapeutic target in cancer. Expert Opin Investig Drugs (2007) 1.27
Glucocorticoid regulation of alkaline phosphatase in the osteoblastic osteosarcoma cell line ROS 17/2.8. Endocrinology (1985) 1.20
Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone. Int J Oncol (2008) 1.20
Targeted disruption of cadherin-11 leads to a reduction in bone density in calvaria and long bone metaphyses. J Bone Miner Res (2001) 1.16
ANTI-ADHESION evolves to a promising therapeutic concept in oncology. Curr Med Chem (2008) 1.15
The cadherin-11 cytoplasmic juxtamembrane domain promotes alpha-catenin turnover at adherens junctions and intercellular motility. Mol Biol Cell (2006) 1.10
Cadherin-11 interacts with the FGF receptor and induces neurite outgrowth through associated downstream signalling. Cell Signal (2008) 1.06
Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol (2010) 1.04
Uncoupling of XB/U-cadherin-catenin complex formation from its function in cell-cell adhesion. J Biol Chem (1997) 1.04
Biology and clinical management of prostate cancer bone metastasis. Front Biosci (2007) 1.04
Simultaneous expression of cadherin-11 in signet-ring cell carcinoma and stromal cells of diffuse-type gastric cancer. Cancer Lett (1996) 1.03
A novel function for cadherin 11/osteoblast-cadherin in vascular smooth muscle cells: modulation of cell migration and proliferation. J Vasc Surg (2007) 0.98
Expression of the extracellular domain of OB-cadherin as an Fc fusion protein using bicistronic retroviral expression vector. Protein Expr Purif (2008) 0.96
A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene (2008) 0.92
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A (2010) 4.95
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02
Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer (2005) 2.86
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci U S A (2006) 2.59
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res (2005) 2.14
SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res (2005) 2.07
Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem (2006) 2.01
Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metab (2005) 1.99
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer (2002) 1.95
Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell (2013) 1.93
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med (2007) 1.92
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87
Regulation of renin in mice with Cre recombinase-mediated deletion of G protein Gsalpha in juxtaglomerular cells. Am J Physiol Renal Physiol (2006) 1.86
Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res (2011) 1.83
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol (2002) 1.74
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol (2004) 1.67
Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res (2008) 1.67
Identification of a novel protein, LYRIC, localized to tight junctions of polarized epithelial cells. Exp Cell Res (2004) 1.59
Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res (2004) 1.56
A role for Plk1 phosphorylation of NudC in cytokinesis. Dev Cell (2003) 1.55
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol (2007) 1.53
Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res (2013) 1.53
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate (2012) 1.53
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49
Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol (2005) 1.44
CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res (2010) 1.42
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res (2007) 1.42
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res (2003) 1.42
Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci U S A (2011) 1.41
Effectiveness of education programs about oral antibiotic suspensions in pediatric outpatient services. Pediatr Neonatol (2012) 1.41
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol (2008) 1.40
Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: a 3-year population-based retrospective cohort study in Taiwan. Clin Ther (2011) 1.40
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res (2014) 1.39
Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol (2004) 1.39
Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst (2010) 1.33
SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity (2006) 1.33
Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut (2011) 1.32
Lack of A1 adenosine receptors augments diabetic hyperfiltration and glomerular injury. J Am Soc Nephrol (2008) 1.32
A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res (2010) 1.32
NudC is required for Plk1 targeting to the kinetochore and chromosome congression. Curr Biol (2006) 1.30
Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Res (2008) 1.30
Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment. Proc Natl Acad Sci U S A (2008) 1.30
Bortezomib as a potential treatment for prostate cancer. Cancer Res (2004) 1.29
SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem (2010) 1.29
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs (2011) 1.24
BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res (2011) 1.23
Adipose tissue-derived stem cells promote prostate tumor growth. Prostate (2010) 1.22
Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res (2008) 1.22
Role for NudC, a dynein-associated nuclear movement protein, in mitosis and cytokinesis. J Cell Sci (2003) 1.21
GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One (2009) 1.20
Nuclear receptor COUP-TFII controls pancreatic islet tumor angiogenesis by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor-2 signaling. Cancer Res (2010) 1.19
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun (2007) 1.19
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis (2007) 1.17
Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res (2011) 1.15
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res (2009) 1.14
Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics (2009) 1.11
Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem (2004) 1.10
Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A (2011) 1.09
Inflammatory breast cancer (IBC): clues for targeted therapies. Breast Cancer Res Treat (2013) 1.08
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst (2011) 1.08
p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis (2002) 1.08
Neogenesis of beta-cells in adult BETA2/NeuroD-deficient mice. Mol Endocrinol (2002) 1.07
Renal function in mice with targeted disruption of the A isoform of the Na-K-2Cl co-transporter. J Am Soc Nephrol (2007) 1.07
A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res (2007) 1.07
Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. Cancer Res (2004) 1.06
Nuclear receptor chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) modulates mesenchymal cell commitment and differentiation. Proc Natl Acad Sci U S A (2011) 1.06
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol (2002) 1.06
Bone marrow-derived cells do not repair endothelium in a mouse model of chronic endothelial cell dysfunction. Cardiovasc Res (2009) 1.05
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol (2009) 1.05